Thymectomy Plus Prednisone Shows Benefit in Patients With Nonthymomatous Myasthenia Gravis
February 10th 2019Five-year results from the extended randomized MGTX trial demonstrated that the addition of thymectomy to prednisone leads to long-lasting lower quantitative myasthenia gravis (QMG) scores and prednisone dosing.
MRD Can't Predict Response in Early Days of Intensive AML Therapy, Study Says
February 9th 2019Molecular minimal residual disease (MRD) testing during the first 4 days of induction therapy does not differentiate responders and nonresponders and should not be used in predicting clinical response for patients with acute myeloid leukemia (AML), according to the results from a recent study.
Ineligibility for Intensive Chemotherapy Impacts QoL Scores, Survival in AML
February 7th 2019Patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy tend to have poor health-related quality of life (HRQoL) scores that are independent predictors of poor survival, a recent study reported.
Long Noncoding RNAs Contribute to Prominent Signaling Pathways in BCP-ALL
February 2nd 2019Long noncoding RNAs (lncRNAs) are involved in the pathogenesis of b-cell precursor acute lymphoblastic leukemia (BCP-ALL) and contribute to the stratification of BCP-ALL subtypes, according to results from a recent study.
Romiplostim Produces Durable Platelet Responses in Pediatric Patients with Immune Thrombocytopenia
January 18th 2019Based on 2 randomized, placebo-controlled studies, the FDA approved romiplostim (Nplate) for pediatric patients 1 year and older with immune thrombocytopenia (ITP) for at least 6 months who do not have sufficient response to other treatments, including corticosteroids, splenectomy, and immunoglobulins.
ctDNA Alone Not a Useful Biomarker of Multiple Myeloma Disease Status, Study Says
January 16th 2019There is a lack in correlation between circulating tumor DNA (ctDNA) and bone marrow for minimal residual disease (MRD) by next generation sequencing (NGS) using immunoglobulin genes in patients with multiple myeloma, according to results of a recent study.
Results From Phase 3 Trial Report Sorafenib Show Positive Results for Treating Desmoid Tumors
January 13th 2019Patients with progressive, symptomatic, or recurrent desmoid tumors who received sorafenib have significantly improved progression-free survival (PFS) rates at 1 and 2 years compared with patients who received placebo, according to the results of a recent phase 3 trial.
Maintenance Therapy for Multiple Myeloma Needs Improvement Beyond Lenalidomide, Study Says
January 12th 2019Maintenance therapy with lenalidomide remains a standard of care for patients with multiple myeloma. However, optimizing maintenance therapy in this setting is required as a result of lenalidomide’s lack of overall survival benefit and improvement in outcomes for patients with high-risk cytogenic abnormalities, according to a recent study.
Phase 2 Study of Combo Therapy Shows Promise for Patients With Mantle Cell Lymphoma
January 9th 2019A phase 2 trial demonstrated that the regimen of rituximab, bortezomib, bendamustine, and dexamethasone is a viable treatment option for older patients with mantle cell lymphoma (MCL), and highlighted the usefulness of using minimal residual disease (MRD) to guide early and late clinical decisions.
Migraine Prevalence May Be Associated With Spontaneous Coronary Artery Dissection
January 4th 2019Patients with a history of migraine are more likely to develop spontaneous coronary artery dissection at a younger age, have depression, and post-SCAD chest pains compared with patients without a migraine history, according to the results of a recent study.
Early Study Promising for Ruxolitinib, Decitabine for Myeloproliferative Neoplasms
January 3rd 2019A phase 1 trial by showed that decitabine with ruxolitinib was generally well tolerated and displayed promising clinical efficacy in patients with accelerated or blast-phase myeloproliferative neoplasms (MPN-AP/BP).
Genetic Risk Variant Tied to Type of CNS Cell Increases Risk of MS, Study Says
December 29th 2018A genetic risk variant, rs7665090G, located near NFKB1, on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis (MS), according to the results of a recent study.
Childhood Hodgkin Lymphoma Survivors Have Increased Risk of Later Tumors
December 29th 2018Children with Hodgkin lymphoma who are treated during childhood and survive to adulthood have higher incidence rates of breast, lung, colorectal, and thyroid cancer than the general population, according to a recent study.
Abemaciclib Plus Endocrine Therapy May Benefit Patients With Certain Characteristics
December 28th 2018Patients with prognostic characteristics including higher-grade tumors, progesterone receptor (PgR)–negative tumors, liver metastases, and shorter treatment-free intervals derived a greater benefit from the addition of abemaciclib to endocrine therapy (ET) compared with ET alone, according to a recent study.
Similar Incidence Rates of Febrile Neutropenia Between Short- and Long-Acting G-CSFs
December 27th 2018Incidence of febrile neutropenia, hospitalizations, and chemotherapy dose reductions and/or delays were similar between short- and long-acting granulocyte-colony stimulating factors, according to a meta-analysis of randomized controlled trials.
Longer Breastfeeding Duration Shown to Reduce Waist Size Over the Long Term
December 20th 2018Women who breastfed for longer than 6 months had a smaller waist circumference and body mass index (BMI) compared with women who have not breastfed or have breastfed for a shorter duration, according to the results of a recent study.
Increased Monthly Migraine Days Associated With Higher Productivity Loss, Acute Medication Use
December 20th 2018Data from 3 erenumab clinical trials of patients with migraine have identified that an increase in the frequency of monthly migraine days leads to an increase in acute medication use and productivity loss.